Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCDC and NeoDC Vaccine for ESCC
NCT05317325Phase 1Unknown
- Sponsor
- Sichuan University
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OC-DC and NeoDC-Vac in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sichuan University. Primary endpoint: The number of treatment-related adverse events at 3 months. Status: unknown.
02
Drugs
OC-DCNeoDC-Vac
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05317325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05317325.